Ebola crisis: First large-scale vaccine trials to begin

 More than 3,600 people have died from Ebola in Liberia

The first large-scale trials of an experimental vaccine against Ebola are due to begin in Liberia.

The potentially preventative medicine was taken under strict security to a
secret location in the West African country.
Scientists aim to immunise 30,000 volunteers, including front-line health workers.
More than 8,500 people have died in the Ebola outbreak, the vast majority in Guinea, Liberia and Sierra Leone.
The total number of reported cases is more than 21,000. In Liberia alone, more than 3,600 people have died from the disease.
The trial beginning on Monday will involve injecting a small amount of the a strain of the Ebola virus into 12 volunteers in order to trick the body into producing an immune response.
But it is not yet clear whether this will really offer protection against the disease.

Dr Stephen Kennedy explains to Mark Doyle how the vaccine works

The senior Liberian scientist involved in the trials, Stephen Kennedy, told the BBC the volunteers were safe.
"There is no danger because the piece of the Zaire strain that has been put into the vaccine. It is a weak strain and it can not and will not cause Ebola, so it is impossible that anyone of the volunteers will contract Ebola from the vaccine," Mr Kennedy said.
The BBC's Mark Doyle in Liberia says that the scientists are well aware of how important it will be to work with the local people if this trial is to work.
Community nurses are being trained in how to monitor volunteers in the months after they have had their injections.

Duncan Bell, MSF: "We don't want to jump for joy but... it is a step in the right direction"

In the meantime, our correspondent says that parts of the largest Ebola treatment centre in the world, on the edge of Monrovia, are being knocked down.
The number of Ebola cases in Liberia has been steadily decreasing - in recent months, there have only been five confirmed cases across the country.
The World Health Organization says the epidemic has entered a "second phase" with the focus shifting to ending the epidemic.
The survival rate of the current outbreak is around 40%.